Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow FibroBiologics Inc.

Get SEC filing alerts via email and in your feed for FibroBiologics Inc.

FBLG

FibroBiologics Inc.

About FibroBiologics Inc.

FibroBiologics Inc. is a biotech company developing fibroblast-based therapies for chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and certain cancers. Its core platform leverages fibroblasts' regenerative and immunomodulatory properties to create innovative, minimally invasive treatments. The company focuses on preclinical research, clinical trials, and intellectual property to advance regenerative medicine solutions for unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from FibroBiologics Inc.

1
1
FibroBiologics Inc. FibroBiologics Reports $5 Million Net Loss in Q1 2026 Amid Increased R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
FibroBiologics Inc. FibroBiologics Reports $18.6 Million Net Loss and Advances Clinical Pipeline in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
FibroBiologics Inc. FibroBiologics Reports $15.4 Million Net Loss and Prepares for Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
FibroBiologics Inc. FibroBiologics Reports $4.7 Million Net Loss in Q2 2025, Faces Funding Challenges

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
FibroBiologics Inc. FibroBiologics Reports Q1 2025 Financial Results with $4.97 Million Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
FibroBiologics Inc. FibroBiologics Reports $11.161 Million Net Loss for Fiscal Year 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
FibroBiologics Inc. FibroBiologics Reports Mixed Financial Results, Advances Product Candidates Amid Regulatory Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments